MaxCyte (NASDAQ:MXCT) Issues Earnings Results

MaxCyte (NASDAQ:MXCT) announced its quarterly earnings data on Wednesday. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01, FiscalAI reports. The company had revenue of $6.50 million during the quarter, compared to the consensus estimate of $6.51 million. MaxCyte had a negative net margin of 121.16% and a negative return on equity of 20.03%.

Here are the key takeaways from MaxCyte’s conference call:

• MaxCyte reiterated its 2026 revenue guidance of $30 million–$32 million, with low single-digit year-over-year growth expected in the second half as instrument placements recover and prior inventory and partner-program headwinds subside.
• The new enterprise-level Genentech partnership provides access to MaxCyte’s ExPERT GTx, electroporation, and SeQure technologies across multiple programs and development stages, potentially creating recurring license, platform-use, instrument, consumables, and milestone revenue.
• Commercial momentum for Vertex’s CASGEVY continued, with approximately $76 million in second-quarter sales and more than 100 patient treatment initiations; MaxCyte’s SPL-related revenue rose to $0.8 million from $0.3 million a year earlier.
• Management reported broad stabilization in instrument and processing-assembly demand, early traction for the DTx platform, and expects instrument revenue to be the primary growth driver in the second half; it also sees potential commercial launches from five partner programs over the next few years, mainly in 2027.
• Second-quarter revenue declined 15% year over year to $7.3 million, while core revenue fell 21%; gross margin also decreased to 77% from 82% and is expected to remain in the mid-70% range as instrument revenue represents a larger mix.

MaxCyte Trading Up 2.4%

Shares of NASDAQ:MXCT traded up $0.03 on Wednesday, hitting $1.27. The company had a trading volume of 1,896,727 shares, compared to its average volume of 1,105,043. The stock has a market cap of $136.04 million, a price-to-earnings ratio of -3.43 and a beta of 1.48. The stock has a 50 day moving average price of $1.19 and a 200 day moving average price of $0.98. MaxCyte has a 1-year low of $0.64 and a 1-year high of $1.86.

Analyst Ratings Changes

Several equities research analysts recently issued reports on MXCT shares. Wall Street Zen upgraded shares of MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, MaxCyte has an average rating of “Hold” and an average price target of $5.00.

Institutional Trading of MaxCyte

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Prudential Financial Inc. bought a new position in MaxCyte in the 2nd quarter valued at about $26,000. State of Wyoming bought a new stake in shares of MaxCyte during the second quarter worth approximately $38,000. Jain Global LLC acquired a new position in shares of MaxCyte in the fourth quarter valued at approximately $45,000. BNP Paribas Financial Markets grew its position in shares of MaxCyte by 266.6% in the second quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock valued at $57,000 after purchasing an additional 18,913 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of MaxCyte during the fourth quarter worth approximately $67,000. Institutional investors own 68.81% of the company’s stock.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.